Cargando…
HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone
To date, the majority of HIV-1 phenotypic resistance testing has been performed with subtype B virus backbones (e.g. HXB2). However, the relevance of using this backbone to determine resistance in non-subtype B HIV-1 viruses still needs to be assessed. From 114 HIV-1 subtype C clinical samples (36 A...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322145/ https://www.ncbi.nlm.nih.gov/pubmed/22496845 http://dx.doi.org/10.1371/journal.pone.0034708 |
_version_ | 1782229036984958976 |
---|---|
author | Bronze, Michelle Steegen, Kim Wallis, Carole L. De Wolf, Hans Papathanasopoulos, Maria A. Van Houtte, Margriet Stevens, Wendy S. de Wit, Tobias Rinke Stuyver, Lieven J. |
author_facet | Bronze, Michelle Steegen, Kim Wallis, Carole L. De Wolf, Hans Papathanasopoulos, Maria A. Van Houtte, Margriet Stevens, Wendy S. de Wit, Tobias Rinke Stuyver, Lieven J. |
author_sort | Bronze, Michelle |
collection | PubMed |
description | To date, the majority of HIV-1 phenotypic resistance testing has been performed with subtype B virus backbones (e.g. HXB2). However, the relevance of using this backbone to determine resistance in non-subtype B HIV-1 viruses still needs to be assessed. From 114 HIV-1 subtype C clinical samples (36 ARV-naïve, 78 ARV-exposed), pol amplicons were produced and analyzed for phenotypic resistance using both a subtype B- and C-backbone in which the pol fragment was deleted. Phenotypic resistance was assessed in resulting recombinant virus stocks (RVS) for a series of antiretroviral drugs (ARV's) and expressed as fold change (FC), yielding 1660 FC comparisons. These Antivirogram® derived FC values were categorized as having resistant or sensitive susceptibility based on biological cut-off values (BCOs). The concordance between resistance calls obtained for the same clinical sample but derived from two different backbones (i.e. B and C) accounted for 86.1% (1429/1660) of the FC comparisons. However, when taking the assay variability into account, 95.8% (1590/1660) of the phenotypic data could be considered as being concordant with respect to their resistance call. No difference in the capacity to detect resistance associated with M184V, K103N and V106M mutations was noted between the two backbones. The following was concluded: (i) A high level of concordance was shown between the two backbone phenotypic resistance profiles; (ii) Assay variability is largely responsible for discordant results (i.e. for FC values close to BCO); (iii) Confidence intervals should be given around the BCO's, when assessing resistance in HIV-1 subtype C; (iv) No systematic resistance under- or overcalling of subtype C amplicons in the B-backbone was observed; (v) Virus backbone subtype sequence variability outside the pol region does not contribute to phenotypic FC values. In conclusion the HXB2 virus backbone remains an acceptable vector for phenotyping HIV-1 subtype C pol amplicons. |
format | Online Article Text |
id | pubmed-3322145 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-33221452012-04-11 HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone Bronze, Michelle Steegen, Kim Wallis, Carole L. De Wolf, Hans Papathanasopoulos, Maria A. Van Houtte, Margriet Stevens, Wendy S. de Wit, Tobias Rinke Stuyver, Lieven J. PLoS One Research Article To date, the majority of HIV-1 phenotypic resistance testing has been performed with subtype B virus backbones (e.g. HXB2). However, the relevance of using this backbone to determine resistance in non-subtype B HIV-1 viruses still needs to be assessed. From 114 HIV-1 subtype C clinical samples (36 ARV-naïve, 78 ARV-exposed), pol amplicons were produced and analyzed for phenotypic resistance using both a subtype B- and C-backbone in which the pol fragment was deleted. Phenotypic resistance was assessed in resulting recombinant virus stocks (RVS) for a series of antiretroviral drugs (ARV's) and expressed as fold change (FC), yielding 1660 FC comparisons. These Antivirogram® derived FC values were categorized as having resistant or sensitive susceptibility based on biological cut-off values (BCOs). The concordance between resistance calls obtained for the same clinical sample but derived from two different backbones (i.e. B and C) accounted for 86.1% (1429/1660) of the FC comparisons. However, when taking the assay variability into account, 95.8% (1590/1660) of the phenotypic data could be considered as being concordant with respect to their resistance call. No difference in the capacity to detect resistance associated with M184V, K103N and V106M mutations was noted between the two backbones. The following was concluded: (i) A high level of concordance was shown between the two backbone phenotypic resistance profiles; (ii) Assay variability is largely responsible for discordant results (i.e. for FC values close to BCO); (iii) Confidence intervals should be given around the BCO's, when assessing resistance in HIV-1 subtype C; (iv) No systematic resistance under- or overcalling of subtype C amplicons in the B-backbone was observed; (v) Virus backbone subtype sequence variability outside the pol region does not contribute to phenotypic FC values. In conclusion the HXB2 virus backbone remains an acceptable vector for phenotyping HIV-1 subtype C pol amplicons. Public Library of Science 2012-04-09 /pmc/articles/PMC3322145/ /pubmed/22496845 http://dx.doi.org/10.1371/journal.pone.0034708 Text en Bronze et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Bronze, Michelle Steegen, Kim Wallis, Carole L. De Wolf, Hans Papathanasopoulos, Maria A. Van Houtte, Margriet Stevens, Wendy S. de Wit, Tobias Rinke Stuyver, Lieven J. HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone |
title | HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone |
title_full | HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone |
title_fullStr | HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone |
title_full_unstemmed | HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone |
title_short | HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone |
title_sort | hiv-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322145/ https://www.ncbi.nlm.nih.gov/pubmed/22496845 http://dx.doi.org/10.1371/journal.pone.0034708 |
work_keys_str_mv | AT bronzemichelle hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone AT steegenkim hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone AT walliscarolel hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone AT dewolfhans hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone AT papathanasopoulosmariaa hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone AT vanhouttemargriet hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone AT stevenswendys hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone AT dewittobiasrinke hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone AT stuyverlievenj hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone AT hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone |